News
Biologicals dominate Europe’s best sellers
2015-03-18 The landscape of blockbuster medicines in Europe has been changing over the last years from small molecule drugs to biologicals. Biologicals now dominate the top… Read More »
Influence of CETA on generics
2015-03-16 On 18 October 2013, the European Union (EU) and Canada reached a political agreement on the key elements for a Comprehensive Economic and Trade Agreement… Read More »
ECCO position statement on biosimilars
2015-03-12 The European Crohn’s and Colitis Organisation (ECCO) is a non-profit association with the aim of improving the care of patients with inflammatory bowel disease (IBD)… Read More »
Factors influencing use of generic asthma drugs in Morocco
2015-03-10 Despite the introduction of methods to promote the use of generics, use of generic anti-asthmatic drugs remains limited in Morocco. The Moroccan market therefore remains… Read More »
EMA criticized for change in data transparency plans
2015-03-06 New Legislation approved by the European Parliament on 2 April 2014 aims to increase transparency with respect to clinical trials by making the results publicly… Read More »
Factors supporting a sustainable European biosimilars market
2015-03-04 Factors that will support a sustainable biosimilars market in Europe include education, encouraging competition, publication of real-world evidence and transparent decision-making processes, according to a… Read More »
Can the pursuit of biosimilar interchangeability go too far?
2015-03-02 The question of biosimilar interchangeability – whether or not a biosimilar can safely be switched with another biosimilar or with the originator product – is… Read More »
Europe–Japan cooperation on generics and biosimilars regulation
2015-02-26 Japanese and European generics groups have met to discuss increase regulatory cooperation between the two regions. The Japanese Generic Medicines Association (JGA), the Nippon Keidanren… Read More »
Top 8 blockbuster biologicals 2013
2015-02-24 The top three best-selling drugs during 2013 were biologicals. All three best-sellers are indicated for the treatment of arthritis, and include Abbott’s Humira (adalimumab), Merck’s… Read More »
Impact of price cuts on spending on hyperlipidaemic drugs in South Korea
2015-02-20 Rapidly increasing pharmaceutical expenditures have become a constant challenge to the sustainability of healthcare systems across countries including Korea. Policies for pharmaceuticals can be divided… Read More »
